Abstract:Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions.

Overcoming Current Dilemma in Cartilage Regeneration: Will Direct Conversion Provide a Breakthrough?

Direct Reprogramming in Bone and Joint Degenerative Diseases: Applications, Obstacles and Directions

Strategies for Directing the Differentiation of Stem Cells into the Osteogenic Lineage in Vitro

Directing stem cell differentiation into the chondrogenic lineage in vitro.

Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis

Adipose-derived stem cells in articular cartilage regeneration: current concepts and optimization strategies.

Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions

Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals

Non-viral approaches for direct conversion into mesenchymal cell types: Potential application in tissue engineering

Advancements in Inflammation Control and Cartilage Regeneration

Combating Osteoarthritis through Stem Cell Therapies by Rejuvenating Cartilage: A Review

Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration

Cell Therapy Approaches for Articular Cartilage Regeneration

Direct cell reprogramming for tissue engineering and regenerative medicine

Recent advancements in cartilage tissue engineering innovation and translation

Current Research on Pharmacologic and Regenerative Therapies for Osteoarthritis

Protecting the regenerative environment: selecting the optimal delivery vehicle for cartilage repair—a narrative review

Cartilage Tissue Engineering Using Stem Cells and Bioprinting Technology—Barriers to Clinical Translation

Advancing Scaffold-Assisted Modality for In Situ Osteochondral Regeneration: A Shift From Biodegradable to Bioadaptable

Innovative Tissue‐Engineered Strategies for Osteochondral Defect Repair and Regeneration: Current Progress and Challenges

Strategies to Convert Cells into Hyaline Cartilage: Magic Spells for Adult Stem Cells